Skip to main content
. Author manuscript; available in PMC: 2021 May 15.
Published in final edited form as: J Alzheimers Dis. 2021;79(3):1235–1255. doi: 10.3233/JAD-201099

Fig. 7.

Fig. 7.

DSS treatment reduced microglia phagocytic phenotype in AppNL-G-F mice but altered microgliosis and astrocytosis in wild types. Immunohistochemistry was performed on both WT and AppNL-G-F brains using anti-GFAP, Iba-1, and CD68 antibodies. Mean optical density was measured using 3 hippocampal sections/mouse/condition. Representative hippocampi are shown with 4X and 20X magnifications, (*p<0.05, unpaired two-tailed t-test indicate WT GFAP t(14)=2.289 and p=0.0381; AppNL-G-F GFAP t(13)=0.4900 and p=0.6323; WT Iba-1 t(8)=2.533 and p=0.0351; AppNL-G-F Iba-1 t(8)=0.4805 and p=0.6438; WT CD68 t(8)=0.8152 and p=0.4386; AppNL-G-F CD68 t(9)=2.606 and p=0.0285, mean ± SEM, n=5–9 animals).